Finalists Revealed for the 2016 Giants of Cancer Care Awards

Tony Berberabe, MPH @OncBiz_Wiz
Published: Friday, Jun 03, 2016
2016 Giants of Cancer Care An elite group of finalists have been recognized for their achievements, talent, and the compassionate care they provide to their patients and families in the 2016 Giants of Cancer Care® recognition program. The group is being honored and celebrated as the pioneers, innovators, and future generations of leaders for their remarkable achievements in oncology research and clinical practice.

Now in its fourth year, the Giants of Cancer Care recognition program honors renowned physicians and researchers who have devoted their time, talent, and resources to improving the care for patients and families who are affected by cancer. Their discoveries have propelled the field forward and established the building blocks for future advances. Recipients demonstrate the qualities that distinguish this award from others: unlimited selflessness, compassion for their patients, and a desire to understand and develop lifechanging treatments against a disease that affects so many.

A total of 46 finalists were unveiled in 10 categories—breast cancer, community outreach/education, gastrointestinal cancer, genitourinary cancer, hematologic cancer, lung cancer, melanoma, radiation oncology, scientific advances, and surgical oncology during a gala event, “An Evening Under the Stars” on June 2, 2016 in Chicago. The finalists were chosen from nearly 200 nominations submitted by the public from November 2015 through March 2016. The Advisory Board of the Giants of Cancer Care then winnowed the field to these nominees.

This year’s winners will be chosen by a selection committee made up of eminent oncologists, educators, clinicians and researchers. The committee will consider each finalist’s body of work, including clinical impact, significant contributions, and overall accomplishments. The winners will be announced at the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® to be held November 9-11 at the New York Marriott Marquis in New York City.

Here’s to the finalists!

BREAST CANCER

Larry Norton, MD

Larry Norton, MD

Sarofim Chair of Clinical Oncology Director, Lauder Breast Center,
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill-Cornell Medical College

Developed an approach to therapy called “dose density,” or “sequential dose density.” This is a new and more effective way of using anticancer drugs, based on a mathematical model, which maximizes the destruction of cancer cells while minimizing toxicity.
Norman Wolmark, MD

Norman Wolmark, MD

Chairman, NSABP Foundation
Medical Director Allegheny Health Network (AHN) Cancer
Institute Research

Chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and principal investigator of the NCI-funded NRG Cooperative Group. He was instrumental in preventing the demise of the NSABP, which has a nearly 60-year history of conducting groundbreaking research studies in breast and colorectal cancer. The NSABP has research sites at nearly 700 major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the United States, Canada, and Ireland.
Sandra Swain, MD

Sandra Swain, MD

Washington Cancer Institute
Medical Director
Georgetown University
Professor of Medicine

Her research addresses some of the barriers to clinical trial participation through the INSPIRE study, which has been successful in increasing the number of Black patients who consent/ participate in breast cancer therapeutic trials at MedStar hospitals.
Martine Piccart, MD, PhD

Martine Piccart, MD, PhD

Université Libre de Bruxelles
Professor of Oncology
Institute Jules Bordet, Brussels, Belgium
Director of Medicine

With a primary interest in breast cancer and drug development, Dr Piccart is a leader in international research collaboration and is the principal or co-principal investigator of many clinical trials, including HERA, MINDACT, and ALTTO. She is co-founder and chair of the Breast International Group (BIG), uniting 49 academic research groups from around the world and running over 30 trials under its umbrella.
Umberto Veronesi, MD

Umberto Veronesi, MD

European Institute of Oncology
Scientific Director
Order of Merit of the Italian Republic
Knight Grand Cross

Founder of breast-conserving surgery in breast cancer treatment using the the technique of quadrantectomy, which challenged the idea, then dominating among surgeons, that cancer could only be treated with aggressive surgery.

Community Outreach

Julie Gralow, MD

Julie Gralow, MD

Jill Bennett Endowed Professor of Breast
Professor of Oncology
Cancer and Professor of Global Health
University of Washington School of Medicine
Director, Breast Medical Oncology, Seattle Cancer Care Alliance
Member, Fred Hutchinson Cancer Research Center

Dr Gralow, a noted breast cancer researcher, is the founder, medical director, and team physician of Team Survivor Northwest, a nonprofit that provides fitness and health education programs to enable women cancer survivors, in any stage of treatment or recovery and at any fitness level, to take an active role in their physical and emotional healing.
Jill O’Donnell-Tormey, PhD

Jill O’Donnell-Tormey, PhD

Cancer Research Institute
Chief Executive Officer
Director of Scientific Affairs

Dr O’Donnell-Tormey was at the heart of a collaboration between the Cancer Research Institute and the Ludwig Institute for Cancer Research to develop a worldwide network of scientists and clinicians focused on understanding the immunological response to cancer and harnessing that knowledge for patient benefit. The result was the creation of the Cancer Vaccine Collaborative.
Joyce O’Shaughnessy, MD

Joyce O’Shaughnessy, MD

Baylor-Sammons Cancer Center
Co-chair, Breast Cancer Research
Chair, Breast Cancer
Prevention Research

Dr O’Shaughnessy is the Celebrating Women Endowed Chair in Breast Cancer Research at the Baylor-Charles A. Sammons Cancer Center. She has made significant contributions to breast cancer care by helping to design and oversee clinical trials leading to the FDA approval of gemcitabine (Gemzar) and capecitabine (Xeloda). She also was involved in the original clinical trials of paclitaxel (Taxol) and other breast cancer regimens.
Tatiana M. Prowell, MD

Tatiana M. Prowell, MD

Johns Hopkins University School of Medicine
Assistant Professor of Oncology

Dr Prowell pioneered a novel pathway to accelerated approval for drugs to treat high-risk, early-stage breast cancer in the neoadjuvant setting. This resulted in accelerated approval of pertuzumab (Perjeta), which substantially prolongs survival in metastatic HER2-positive breast cancer. She is the three-time recipient of FDA’s Excellence in Communication Award.

Gastrointestinal Cancer

Charles S. Fuchs, MD, MPH

Charles S. Fuchs, MD, MPH

Director, Center for Gastrointestinal Cancer
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School

He leads the Dana-Farber/Harvard Cancer Center Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers. Dr Fuchs splits his time between laboratory-based research, clinical research, and clinical care. His laboratory focuses on biochemical markers of GI cancer risk, molecular predictors of patient outcome, and the discovery of novel targets for therapy for patients with gastric, colorectal, and pancreatic cancers.
Richard Goldberg, MD

Richard Goldberg, MD

Physician-in-Chief of the James Cancer
Hospital and Solove Research Institute
Acting Director of the Division of Medical Oncology
Associate Director of The Ohio State
University Comprehensive Cancer Center

Dr Goldberg’s New England Journal of Medicine study demonstrated significant and long-lasting benefit in patients whose cancers manifest microsatellite instability and were treated with the PD-1 inhibitor pembrolizumab. Dr Goldberg was the principal investigator of the phase III N9741 study of the combination of IFL, FOLFOX, and FOLFIRI in patients with previously untreated metastatic colorectal cancer that led to the FDA approval of the use of FOLFOX in first-line treatment.
Leonard Saltz, MD

Leonard Saltz, MD

Chief, Gastrointestinal Oncology Service
Head, Colorectal Oncology Section
Memorial Sloan Kettering Cancer Center

Serves on the National Cancer Institute (NCI) Rectal and Anal Cancer Task Force and is co-leader of the Alliance NCI Cooperative Research Group efforts in colon and rectal cancers. Also serves on three National Comprehensive Cancer Network (NCCN) guidelines committees: colorectal cancers, neuroendocrine cancers, and unknown primary cancers.
Margaret Tempero, MD

Margaret Tempero, MD

University of California San Francisco
Director, UCSF Pancreas Center
Leader, Pancreas Cancer Program
Professor of Medicine
Division of Hematology and Oncology
University of California San Francisco

Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.
Daniel Von Hoff, MD

Daniel Von Hoff, MD

Physician in Chief
Director, Translational Research
Translational Genomics Research Institute (TGEN)

Dr Von Hoff and his colleagues were involved in the development of many agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. Currently, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Genitourinary Cancer

Dean F. Bajorin, MD

Dean F. Bajorin, MD

Medical Oncologist
Frederick R. Adler Senior Faculty Chair
Memorial Sloan Kettering Cancer Center

Helped ASCO shape a new strategic plan to address the looming shortage of oncologists in the United States by 2020, including the development of innovative practice arrangements. Currently the chair-elect for the Professional Development Committee, which oversees ASCO’s efforts in career development, lifelong learning, and fellowship training for oncologists.
Charles Drake, MD, PhD

Charles Drake, MD, PhD

Johns Hopkins University School of Medicine
Associate Professor of Oncology, Urology, and Immunology
Co-director of the Prostate Cancer Multidisciplinary Clinic

His research seeks to understand the T-cell response to evolving tumors at a cellular and genetic level with the aim of using this information to develop integrated immunotherapy strategies for patients with cancer.
Celestia S. Higano, MD

Celestia S. Higano, MD

Professor of Medicine and Urology
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle Cancer Alliance

Dr Higano conducts clinical/translational research in prostate cancer. Her group has been directly involved in the development of sipuleucel- T, enzalutamide, abiraterone, and radium 223. She is principal investigator on several on-going phase III trials. Her own research focuses on using intermittent androgen suppression to study the side effects of androgen deprivation therapy.
Robert J. Motzer, MD

Robert J. Motzer, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center

Led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical trials. His research has helped to identify five targeted drugs— sunitinib (Sutent), pazopanib (Votrient), axitinib (Inlyta), temsirolimus (Torisel), and everolimus (Afinitor)—as effective treatments for patients with advanced kidney cancer.
Nicholas Vogelzang, MD

Nicholas Vogelzang, MD

US Oncology, Comprehensive Cancer Center of Nevada
Medical Director, US Oncology Research
Executive Committee
Associate Chair for the Genitourinary and Developmental Therapeutics Programs

He directed the largest phase II trial for mesothelioma using the combination therapy of pemetrexed (Alimta) and cisplatin, resulting in tumor shrinkage in 41% of patients. Dr Vogelzang also led research for two FDA-approved prostate cancer treatments, sipuleucel-T (Provenge) and radium-223 (Xofigo). He was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, and chair of the CALGB Prostate Committee from 1993 to 1999. He is a founding board member of the Mesothelioma Applied Research Foundation (MARF).

Hematologic Cancer

Fred R. Applebaum, MD

Fred R. Applebaum, MD

Executive Director and President
Seattle Cancer Care Alliance

As part of the Southwest Oncology Group, he formed the first multicenter bone marrow transplant clinical trials group. This concept eventually evolved into the federally funded Bone Marrow Transplant Clinical Trials Network. Key contributor to the discovery and development of gemtuzumab ozogamicin (Mylotarg), the first monoclonal antibody approved by the FDA to treat acute myeloid leukemia.
James F. Holland, MD

James F. Holland, MD

Professor of Medicine, Hematology, and Medical Oncology
Professor of Oncological Sciences
Mount Sinai Tisch Cancer Institute

Distinguished Professor of Neoplastic Diseases at the Icahn School of Medicine at Mount Sinai in New York. His 1953 clinical trial on acute leukemia resulted in the formation of Acute Leukemia Group B, a research collaboration that later became known as the Cancer and Leukemia Group B. He is considered a key figure in the development of cancer chemotherapy.
Kanti R. Rai, MD

Kanti R. Rai, MD

Chief, Chronic Lymphocytic Leukemia
Research and Treatment Program
North Shore-LIJ

Leader during the past 4 decades, in leukemia research, specifically in chronic lymphocytic leukemia (CLL). Developed prognostic criteria in CLL in 1975, which are still recognized all over the world as the Rai Staging System.
Margaret A. Shipp, MD

Margaret A. Shipp, MD

Professor of Medicine, Harvard Medical School
Director, Lymphoma Program, Dana-Farber Cancer Institute

Her work characterized the molecular basis for the recognized clinical heterogeneity in diffuse large B-cell lymphoma (DLBCL). Earlier studies focused on specific genes and pathways implicated in the biology of normal and malignant lymphoid progenitors. Her research defined three discrete subsets of DLBCLs: oxidative phosphorylation, B-cell receptor/proliferation, and host response tumors.

Lung Cancer

David Ettinger, MD

David Ettinger, MD

Alex Grass Professor in Oncology
Johns Hopkins University

Member of the Board of Directors of the NCCN as well as a member of the NCCN Guidelines Steering Committee. In addition, he has been chairman of the NCCN non– small cell lung cancer practice guidelines panel, the antiemetic practice guidelines panel, and the occult primary tumor practice guidelines panel.
Waun Ki Hong, MD

Waun Ki Hong, MD

Head, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

His landmark studies demonstrating that high-dose retinoic acid can reverse oral premalignant lesions and prevent the development of second primary tumors were the first to prove that chemoprevention can work in humans.
Bruce E. Johnson, MD

Bruce E. Johnson, MD

Chief, Clinical Research Officer
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School

Johnson leads the Lung Cancer Program where he and fellow researchers identified subsets of patients with adenocarcinoma of the lung who respond differently to targeted agents. Johnson’s laboratory continues to study the relationship between different mutations in the epidermal growth factor receptor, their susceptibility to different epidermal growth factor receptor inhibitors, and the signaling pathways.
Karen Kelly, MD

Karen Kelly, MD

Associate Director for Clinical Research
UC Davis Comprehensive Cancer Center

Her lung cancer research spans the spectrum of the disease from prevention to treatment. She has been at the forefront of clinical trial development evaluating drugs to treat lung cancer and novel compounds to prevent lung cancer.

Melanoma

Thomas Gajewski, MD

Thomas Gajewski, MD

Professor of Medicine
University of Chicago

Investigates and develops new treatments for patients with melanoma, and has a particular interest in the molecular and cellular regulation of T-lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote antitumor immunity in vivo.
F. Stephen Hodi, Jr, MD

F. Stephen Hodi, Jr, MD

Director, Melanoma Center
Director, Center for Immuno-Oncology
Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center
Associate Professor of Medicine
Harvard Medical School

His laboratory is focused on the manipulation of genes that encode for immunomodulators like cytokines and tumor antigens.
John A. Thompson, MD

John A. Thompson, MD

Co-Director of Melanoma Clinic
Seattle Cancer Care Alliance

Dr Thompson’s research efforts focus on the role of immunotherapy in cancer, especially activated lymphocytes and cytokines, and the use of stem cell transplants for kidney cancer and melanoma. Dr. Thompson serves as principal investigator on numerous trials including two national, randomized phase III trials of the allogeneic tumor lysate vaccine Melacine (SWOG 9035).
Jeffrey S. Weber, MD, PhD

Jeffrey S. Weber, MD, PhD

Deputy Director and Co-Director of the Melanoma Program
Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center

His research, which has been continuously funded by the NCI for over 20 years, focuses on experimental therapeutics and drug development, particularly in the areas of immunotherapy and checkpoint inhibitory antibody development in melanoma and other types of cancer. Specifically, his laboratory monitors and characterizes how T cells respond in patients with cancer who are undergoing immune therapy.
Jeffrey Sosman, MD

Jeffrey Sosman, MD

Co-Leader, Translational Research in Solid Tumors (TRIST) Program
Director of the Melanoma Program
Director for Faculty Development, Lurie Cancer Center
Professor of Medicine, Feinberg School of Medicine Northwestern University

Dr Sosman is widely recognized for his initiatives to bring translational medicine to melanoma therapy. His research includes the study of this most deadly form of skin cancer that has seen great breakthroughs in both targeted therapy and immune-based therapy in recent years.

Radiation Oncology

Ralph Weichselbaum, MD

Ralph Weichselbaum, MD

Daniel K. Ludwig Distinguished Service
Professor of Radiation and Cellular Oncology
University of Chicago

His research interests include mechanisms of tumor spread and how radiation therapy and immunotherapy can be used to better treat cancer. He is also studying patterns of gene expression in human tumors that confer resistance to radiotherapy and chemotherapy.
Samuel Hellman, MD

Samuel Hellman, MD

Former Dean and A. N. Pritzker Professor of the Division of Biological Sciences
University of Chicago

Active in both clinical and laboratory investigation, Dr Hellman has been involved in studies of breast cancer, prostate cancer, and lymphoma. The breast cancer studies are of conservative management and the natural history of regionally treated disease. Both of these studies emphasize the importance of understanding the clinical evolution of the disease in order to develop effective multidisciplinary therapy.
Sarah S. Donaldson, MD

Sarah S. Donaldson, MD

Catharine and Howard Avery Professor of Radiation Oncology
Stanford University

Her clinical focus is on pediatric radiation oncology (solid tumors, lymphomas, CNS tumors, and stem cell transplantation), soft tissue sarcoma (rhabdomyosarcoma, non-rhabdomyosarcoma, and bone tumors); eye and orbital diseases; breast cancer; rare benign and malignant tumors; late effects of cancer and its treatment.
Thomas A. Buchholz, MD

Thomas A. Buchholz, MD

Executive Vice President and Physician- in-Chief
The University of Texas MD Anderson Cancer Center

In his role as physician-in-chief, Dr Buchholz is responsible for the clinical faculty and clinical care provided in MD Anderson’s Houston hospital and ambulatory clinics.

Scientific Advances

Lewis C. Cantley, PhD

Lewis C. Cantley, PhD

Meyer Director of the Sandra and Edward
Meyer Cancer Center at Weill Cornell Medical College
Ronald P. Stanton Clinical Cancer Program at New York-Presbyterian
Professor of Cancer Biology in Medicine

His seminal discovery was the pathway phosphoinositide 3-kinase (PI3K) pathway in 1984, with fundamental implications in our understanding of cancer metabolism and insulin signaling. He subsequently mapped the upstream regulation of PI3K and the downstream signaling pathways. The first drug targeting the PI3K pathway as a treatment for cancer—the PI3K-delta inhibitor idelalisib— was approved by the FDA as a treatment for leukemia and two types of lymphoma in July 2014.
Carlo Croce, MD

Carlo Croce, MD

Professor and Chair
Department of Molecular Virology, Immunology and Medical Genetics
Ohio State University

Dr Croce has made seminal contributions to basic and translational research through positional cloning and characterization of genes at chromosomal translocation breakpoints in cancer cells, permitting identification and subsequent characterization of oncogenes and tumor suppressor genes (both protein coding and non–protein-coding genes), with key contributions to cancer development.
Michelle Le Beau, PhD

Michelle Le Beau, PhD

Arthur and Marian Edelstein Professor,
Department of Medicine
Director, The University of Chicago Comprehensive Cancer Center (UCCCC)
Director, Cancer Cytogenetics Laboratory

With more than 410 peer-reviewed publications, her research focuses on: (1) the molecular cloning of a myeloid leukemia-related gene involved in the –5/del(5q) characteristic of acute myeloid leukemia (t-AML); (2) genomic profiling and the identification of genetic pathways leading to t-AML; (3) genetic characterization of murine models recapitulating the genetic mutations in AML; and (4) elucidation of the mechanism for the genetic instability characteristic of chromosomal fragile sites.
John Mendelsohn, MD

John Mendelsohn, MD

Professor, Department of Genomic Medicine, Division of Cancer Medicine
Past President of The University of Texas MD Anderson Cancer Center

He and Gordon Sato, and their collaborators in California, produced monoclonal antibody 225, which inhibits human cancer cell proliferation by blocking the signaling pathways that are activated by epidermal growth factor receptors. His subsequent research in the laboratory and clinic pioneered the universally adopted concept of anti-receptor therapy that targets key cell signaling pathways as a new form of cancer treatment.
Mark J. Ratain, MD

Mark J. Ratain, MD

Leon O. Jacobson Professor of Medicine
Director, Center for Personalized Therapeutics
Associate Director for Clinical Sciences
Comprehensive Cancer Center
The University of Chicago

Dr Ratain is an international leader in phase I clinical trials, pharmacogenetics, and clinical trial methodology. He has more than 260 original publications, leads the University of Chicago’s phase I oncology trials program, serves as chief hospital pharmacologist for the University of Chicago Medical Center.

Surgical Oncology

Sir Murray F. Brennan, MD

Sir Murray F. Brennan, MD

Vice President for International Programs
Benno C. Schmidt Chair in Clinical Oncology
Director, The Bobst International Center
Memorial Sloan Kettering Cancer Center

He created the world’s largest database of sarcoma patients, which includes more than 10,000 patients treated at MSK since 1982. Based on this extensive information, his team has developed computer programs that predict local recurrence and survival for individual patients.
John L. Cameron, MD

John L. Cameron, MD

Professor of Surgery
The Johns Hopkins University School of Medicine

He has won worldwide acclaim for mastering the Whipple procedure in pancreatic cancer. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30%. He has worked to lower that to 1% to 2% at Johns Hopkins.
David Sugarbaker, MD


David Sugarbaker, MD

Professor and Chief
Division of General Thoracic Surgery
Baylor College of Medicine

Focused his career on the treatment of pleural mesothelioma. He pioneered the concept of multimodality therapy of mesothelioma including the surgical technique of extrapleural pneumonectomy. He founded The International Mesothelioma Program in Boston in 2002 and The Mesothelioma Treatment Center at Baylor St Luke’s Medical Center in Houston in 2014.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x